EFFICACY OF CETUXIMAB/PANITUMUMAB AFTER PREVIOUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
ALEXANDRA GHERMAN 1#, CĂLIN CAINAP 1,2, ȘTEFAN-CRISTIAN VESA 3, ANDREI DAN HAVASI 2, ALEXANDRA TRIFON 4, SIMONA SORANA CAINAP 5,6*, OVIDIU CRIȘAN 7#, ALEXANDRU IRIMIE 8,9
111th Department of Medical Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 2Department of Medical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuță”, Cluj-Napoca, Romania 3Department of Pharmacology, Toxicology and Clinical Pharmacology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 4The Regional Institute of Gastroenterology and Hepatology “Prof. Dr. O. Fodor”, Cluj-Napoca, Romania 5Department of Paediatric Cardiology, Emergency County Hospital for Children, Pediatric Clinic no 2, Cluj-Napoca, Romania 6Department of Mother and Child, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 7Department of Organic Chemistry, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 811th Department of Oncological Surgery and Gynaecological Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania 9Department of Surgery, The Oncology Institute “Prof. Dr. Ion Chiricuță”, Cluj-Napoca, Romania
*corresponding author: cainap.simona@gmail.com
#Authors with equal contribution.
.

Download Full Article

Abstract:
The optimal sequence of the targeted therapies in metastatic colorectal cancer is not established. We aimed to analyse if previous administration of bevacizumab impacts the response to epidermal growth factor receptor inhibitors in subsequent lines of therapy. It was performed a retrospective analysis on KRAS or KRAS/NRAS wild-type metastatic colorectal cancer patients that received an epidermal growth factor receptor inhibitor in the second or later lines of therapy and their outcomes were analysed according to previous exposure to bevacizumab. 85 metastatic colorectal cancer patients were included, of whom 22 had received previous chemotherapy (group A) and 63 previous chemotherapy plus bevacizumab (group B). The overall survival was significantly higher in the group B (35.6 months versus 24.8 months, p = 0.01). The overall survival and progression-free survival calculated from the start of the epidermal growth factor receptor inhibitor did not significantly differ between the groups. The multivariate analysis revealed that using bevacizumab did not significantly impact the survival. Our results show that previous administration of bevacizumab does not influence the efficacy of epidermal growth factor receptor inhibitors in later lines of treatment.

Top